Novo Nordisk set to finalize $11bn acquisition of Catalent manufacturing sites
Novo Nordisk is set to finalise its acquisition of three Catalent manufacturing sites, marking a pivotal step in its strategy to bolster global manufacturing capabilities ... Read More
Novo Nordisk announces $11bn acquisition of fill-finish sites to boost global manufacturing
In a strategic move to enhance its global manufacturing capabilities, Novo Nordisk has announced a significant acquisition from Novo Holdings A/S, involving three fill-finish sites, ... Read More
Catalent wins contract to manufacture AZD1222 COVID-19 vaccine candidate
US-based Catalent said that its subsidiary Catalent Biologics has bagged a contract to provide vial filling and packaging capacity to AstraZeneca at its manufacturing facility ... Read More